

COVID-19 Vaccination Autumn 2022: Seasonal Booster and Evergreen Offer



Seasonal booster: Autumn 2022 Must have completed a primary course of 2 or 3 doses AND previous dose must have been at least 91 days ago

Eligible cohorts As recommended by JCVI	Age group	Recommended vaccine
- Any adult aged 50 years or over - Individuals in a risk group (as set out in Green Book, Chapter 14a): - Clinical risk group (age ≥5) - Household contacts of people with immunosuppression (age ≥5) - Frontline health or social care workers (age ≥16) - Residents or staff in care homes for older adults - Carers (age ≥16)	18 years or over	Spikevax Bivalent (0.5mL) or Comirnaty Bivalent (0.3mL)
	12 to 17 years	Comirnaty Bivalent (0.3mL)
	5 to 11 years (including 12 year olds in academic Year 7)	Comirnaty 10 Concentrate (0.2mL diluted dose)

Evergreen offer: individuals yet to complete their primary offer If eligible for an Autumn booster, move to seasonal booster table above after completing primary course

Eligible cohort (See Green Book Chapter 14a for full clinical details)	Primary course 2 doses*	Booster A single booster 91 days after 2 nd dose
18 years or over	Comirnaty 30 Concentrate or Spikevax Original	Spikevax Bivalent (0.5mL) or Comirnaty Bivalent (0.3mL)
16 – 17 years	Comirnaty 30 Concentrate	Comirnaty Bivalent (0.3mL)
13 – 15 years, or aged 12 in academic Year 8	Comirnaty 30 Concentrate	Not eligible
5 [†] – 11 years, or aged 12 in academic Year 7	Comirnaty 10 Concentrate	Not eligible
†For those not in a risk group, this one off offer only applies to individuals who turned 5 by 31 August 2022		*Severely immunosuppressed at the time of 1 st or 2 nd primary dose: 2 primary doses PLUS 3 rd primary dose ideally 8 weeks after 2 nd dose (Assume consideration to timing of immunosuppressive therapy is not required unless evidence to the contrary)

Additional information:

- If an eligible individual has not received a booster prior to September 2022, they may be given one in Autumn, and no additional doses are then required
- For those aged 18 or over, **OR** aged 5 or over and are in a risk group, vaccination should ideally be deferred until 4 weeks after onset of COVID-19 symptoms/positive sample, and the interval between 1st and 2nd primary dose should be a minimum of 8 weeks
- For those aged 5-17 years and not in a risk group, both the interval between 1st and 2nd primary doses, and the ideal deferral period following COVID-19 infection, is a minimum of 12 weeks
- When supply of a Bivalent vaccine is not timely, Comirnaty 30 Concentrate may be used for boosters for those aged 12 or over (or Spikevax Original for those aged 18 or over)
- Patient Group Directions (PGD) and National Protocols available [here](#). A local Patient Specific Direction (PSD) can also be used.
- Most individuals can receive an mRNA vaccine. For those exceptional circumstances where an individual aged 18 years or over is unable to safely receive an mRNA vaccine for clinical reasons, Nuvaxovid will be available for primary courses or for off-label use as a booster vaccine at selected sites via a prescriber (PSD only) and following clinical review. Dose Volume **0.5mL IM**.